News
-
More than a year after the FDA approved Satsuma’s Atzumi (STS 101) intranasal dry powder dihydroergotamine for the treatment of migraine in adults, Satsuma parent company SNBL says that it is still trying to find… Read more . . .
-
Vertex has stopped a Phase 1/2 study of VX-522 inhaled RNA therapy for the treatment of cystic fibrosis and has ceased development of the product, the company said in its most recent report of financial… Read more . . .
-
Enterprise Therapeutics announced that a Phase 2 trial of ETD001, an inhaled epithelial sodium channel blocker, met its primary endpoint, demonstrating a statistically significant and clinically relevant improvement in lung function versus placebo after 28… Read more . . .
-
According to Chance Pharmaceuticals, China’s National Medical Products Administration has accepted the company’s NDA for CXG87 budesonide / formoterol DPI for the treatment of asthma. The announcement emphasizes that the formulation is Chance’s own “improved… Read more . . .
-
CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing… Read more . . .
-
CDMO Intertek has announced an expansion of a GMP stability storage facility near Cambridge, UK, noting that the expanded facility offers custom temperature and relative humidity conditions and is suitable for stability testing of a… Read more . . .
-
As RDD 2026 is about to get underway in Phoenix, AZ, USA, some of the meeting sponsors and exhibitors are previewing their conference activities. As always, RDD is sponsored by dozens of organizations that offer… Read more . . .
-
MannKind Corporation announced that it is developing a DPI formulation of MNKD-1501 ralinepag for the treatment of pulmonary arterial hypertension under an agreement with United Therapeutics under a 2018 licensing and collaboration agreement between the companies that… Read more . . .
-
UK-based inhaler developer Merxin Ltd has been awarded a 2026 King’s Award for Enterprise for Innovation, the company announced. Merxin, which is headquartered in King’s Lynn, UK, was launched in 2015 . The award announcement… Read more . . .
-
Copley Scientific has announced the launch of its SRS 100i automated sample recovery system for use with delivered dose uniformity and APSD testing set-ups, including the compendial dose uniformity sample apparatus (DUSA), the Next Generation Impactor (NGI),… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA